T
NKTR icon

TOBAM’s Nektar Therapeutics NKTR Stock Holding History

TOBAM’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-38,894
Closed -$10.6M – 124
2019
Q3 		$10.6M Buy
38,894
+2,123
+6% +$779K 0.69% 52
2019
Q2 		$19.6M Sell
36,771
-5,932
-14% -$2.97M 1.09% 42
2019
Q1 		$21.5M Sell
42,703
-2,018
-5% -$1.2M 1.09% 39
2018
Q4 		$22.1M Buy
44,721
+16,029
+56% +$9.68M 1.06% 34
2018
Q3 		$26.2M Sell
28,692
-3,730
-12% -$3.18M 1.12% 32
2018
Q2 		$23.7M Buy
+32,422
New +$37.4M 0.98% 37

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

TOBAM's NKTR Position: Q4 2019 in Review

TOBAM sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 38,894 shares — an estimated $10.6M sold.

TOBAM first reported a position in NKTR in Q2 2018 and held it in 6 quarters. The position peaked at $26.2M in Q3 2018. 281 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • TOBAM reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • TOBAM sold 38,894 Nektar Therapeutics shares in Q4 2019, an estimated $10.6M.
  • TOBAM first reported a position in Nektar Therapeutics in Q2 2018 and held it in 6 quarters.
  • TOBAM's Nektar Therapeutics position peaked at $26.2M in Q3 2018.
  • 281 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on TOBAM's 13F filing for Q4 2019, filed 10 Feb 2020.